Insider Selling: Edwards Lifesciences Corp (EW) VP Sells $5,084,534.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) VP Huimin Wang sold 33,800 shares of the business’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $150.43, for a total value of $5,084,534.00. Following the transaction, the vice president now directly owns 81,665 shares of the company’s stock, valued at approximately $12,284,865.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Huimin Wang also recently made the following trade(s):

  • On Friday, October 5th, Huimin Wang sold 3,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $152.79, for a total value of $580,602.00.
  • On Wednesday, September 5th, Huimin Wang sold 3,800 shares of Edwards Lifesciences stock. The stock was sold at an average price of $141.73, for a total value of $538,574.00.

NYSE:EW opened at $153.18 on Friday. The stock has a market cap of $31.93 billion, a PE ratio of 40.31, a PEG ratio of 2.01 and a beta of 0.87. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18. Edwards Lifesciences Corp has a 1-year low of $103.20 and a 1-year high of $175.00.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.05. The company had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.84 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.7 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in EW. Bank Hapoalim BM boosted its holdings in Edwards Lifesciences by 10.4% in the second quarter. Bank Hapoalim BM now owns 3,730 shares of the medical research company’s stock valued at $543,000 after acquiring an additional 350 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in Edwards Lifesciences by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 16,336 shares of the medical research company’s stock valued at $2,378,000 after acquiring an additional 355 shares during the last quarter. Wendell David Associates Inc. boosted its holdings in Edwards Lifesciences by 4.0% in the second quarter. Wendell David Associates Inc. now owns 9,548 shares of the medical research company’s stock valued at $1,390,000 after acquiring an additional 363 shares during the last quarter. Global Financial Private Capital LLC boosted its holdings in Edwards Lifesciences by 8.1% in the third quarter. Global Financial Private Capital LLC now owns 4,893 shares of the medical research company’s stock valued at $852,000 after acquiring an additional 367 shares during the last quarter. Finally, Newport Wealth Strategies Inc. boosted its holdings in Edwards Lifesciences by 19.3% in the third quarter. Newport Wealth Strategies Inc. now owns 2,345 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 380 shares during the last quarter. Institutional investors own 82.71% of the company’s stock.

Several brokerages have commented on EW. Citigroup boosted their target price on Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a research note on Tuesday, July 31st. Zacks Investment Research downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Finally, Morgan Stanley boosted their target price on Edwards Lifesciences from $150.00 to $157.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company’s stock. Edwards Lifesciences presently has an average rating of “Buy” and a consensus price target of $156.79.

ILLEGAL ACTIVITY WARNING: This article was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://sportsperspectives.com/2018/11/10/insider-selling-edwards-lifesciences-corp-ew-vp-sells-5084534-00-in-stock.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: What is the S&P 500 Index?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply